Physician profile
Alan B Erdmann
NPI 1457693608
$5,325.63
in general payments reported to CMS, 2019-2025
30 companies · $1,427 in 2025
The $1,427 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $318 · 2021: $713 · 2022: $374 · 2023: $823 · 2024: $1,229 · 2025: $1,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,304 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,303.53 |
| Education | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,530.14 | 2019-2025 | |
| Janssen Biotech, INC. | $819.35 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $660.48 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $343.00 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $254.96 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $226.42 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.27 | 2019-2025 | Relistor, Trulance |
| Aimmune Therapeutics, INC. | $170.33 | 2024-2025 | Zenpep, Vowst |
| Boston Scientific Corporation | $138.22 | 2019-2020 | |
| Celgene Corporation | $126.26 | 2022-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $119.75 | 2021-2023 | |
| Gilead Sciences, INC. | $105.45 | 2019-2024 | |
| Daiichi Sankyo INC. | $101.06 | 2020-2022 | |
| Madrigal Pharmaceuticals | $81.63 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $56.45 | 2019-2025 | Sucraid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $50.48 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $49.13 | 2021-2025 | Suflave |
| Fresenius Kabi USA, LLC | $44.66 | 2023 | Idacio |
| Organon LLC | $38.44 | 2022-2025 | Hadlima |
| Genzyme Corporation | $29.79 | 2024 | |
| Merck Sharp & Dohme LLC | $28.06 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $25.84 | 2020 | |
| Ferring Pharmaceuticals INC. | $25.63 | 2021-2022 | |
| Romark Laboratories, Lc | $24.46 | 2019 | |
| Mylan Institutional INC. | $21.09 | 2023 | |
| Ardelyx, INC. | $20.80 | 2025 | Ibsrela |
| Lilly USA, LLC | $14.86 | 2025 | Omvoh |
| Capsovision, INC. | $14.70 | 2025 | Capsocam Plus |
| Novo Nordisk INC | $13.83 | 2025 | Wegovy |
| Alfasigma USA, INC. | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Erdmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.